ArticleJournal of general internal medicine2012
Comorbidities, treatment and ensuing survival in men with prostate cancer.
Article in Journal of general internal medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer.BMC urology · 2026Observational
- Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.Prostate cancer and prostatic diseases · 2023Observational
- Comorbidity burden and health-related quality of life in men with advanced prostate cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Observational
- Comorbidity burden and health-related quality of life in men with advanced prostate cancer.Research square · 2023Article
- Determinants of patient activation and its association with cardiovascular disease risk in chronic kidney disease: A cross-sectional study.Health expectations : an international journal of public participation in health care and health policy · 2021Article
- Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.Clinical rheumatology · 2020Article
- Article
- Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer.Medicine · 2016Article
- Types of chronic conditions combinations and initial cancer treatment among elderly Medicare beneficiaries with localised prostate cancer.International journal of clinical practice · 2016Article
- Diabetes and mortality in patients with prostate cancer: a meta-analysis.SpringerPlus · 2016Review
- Is pathology necessary to predict mortality among men with prostate-cancer?BMC medical informatics and decision making · 2014Article
- Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions.Medical care · 2014Article
- Use of advanced treatment technologies among men at low risk of dying from prostate cancer.JAMA · 2013Article
- Comorbidities, treatment and survival.Journal of general internal medicine · 2012Article
- 80 is the new 60: implications of irrational exuberance regarding longevity on prostate cancer treatment decisions.Journal of general internal medicine · 2012Article
- Association of Patient Comorbidities With Treatment Regret Among Patients With Localized Prostate Cancer - Results From a Population-Based Cohort.Practical radiation oncologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundComorbidity is poorly integrated into prostate cancer decision making.
objectiveWe sought to characterize treatment type and subsequent survival for men with no more than a single comorbid condition. DESIGN AND
participantsWe conducted a retrospective study of 1,031 veterans with non-metastatic prostate cancer diagnosed in 1997-2004 at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers and followed until 2010. We used multivariate analyses to determine probabilities and relative risks of undergoing treatment for each health state and competing-risks regression analyses to model non-prostate cancer mortality.
resultsCompared with subjects without any comorbid conditions, only men with moderate-severe chronic obstructive pulmonary disease were less likely to receive definitive treatment for their prostate cancer (RR 0.74; 95% CI 0.44-0.99). Men with all other individual comorbidities were equally likely as men without comorbidity to receive definitive treatment. Compared with men without any comorbidities, a higher hazard rate for non-prostate cancer mortality was identified among men with diabetes without end-organ damage (HR 2.32; 95% CI 1.32-4.08), peripheral vascular disease (HR 2.77; 95% CI 1.14-6.73), moderate-severe chronic obstructive pulmonary disease (HR 5.46; 95% CI 2.68-11.12), diabetes with end-organ damage (HR 4.27; 95% CI 1.64-11.10), those in need of a mobility device (HR 3.29; 95% CI 1.87-5.80), and men with history of alcoholism (HR 1.77; 95% CI 1.07-2.93).
conclusionMen with comorbid conditions and health states that portend poor prognoses are nonetheless aggressively treated for their prostate cancer. Advancing age modulates this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.